biostudies-literatureGauvain KNational Center for Advancing Translational SciencesAmerican Cancer SocietyNCATS NIH HHSNational Cancer InstituteNCI NIH HHS28-36https://www.ebi.ac.uk/biostudies/studies/S-EPMC5909807biostudies-literatureUnknown5(1)<h4>Background</h4>Noninvasively predicting early response to therapy in recurrent pediatric brain tumors provides a challenge. 3,4-dihydroxy-6-[¹⁸F]fluoro-L-phenylalanine (¹⁸F-FDOPA) PET/MRI has not been previously studied as a tool to evaluate early response to antiangiogenic therapy in children. The purpose of this study was to evaluate the safety and feasibility of using ¹⁸F-FDOPA PET/MRI to assess response to bevacizumab in children with relapsed brain tumors.<h4>Materials and methods</h4>Six patients with recurrent gliomas (5 low-grade, 1 high-grade) planned to undergo treatment with bevacizumab were enrolled. ¹⁸F-FDOPA PET/MRI scans were obtained prior to and 4 weeks following the start of treatment, and these were compared with the clinicNeuro-oncology practice¹⁸F-FDOPA PET/MRI for monitoring early response to bevacizumab in children with recurrent brain tumors.PMC5909807P30 CA091842UL1 TR002345K08 CA154790P30 CA013148IRG-58-010-56K08CA154790Ponisio MRLeeds HGoyal MRubin JBarone AMcConathy JParent EGrimaldi MGauvain Kfalse¹⁸F-FDOPA PET/MRI for monitoring early response to bevacizumab in children with recurrent brain tumors.<h4>Background</h4>Noninvasively predicting early response to therapy in recurrent pediatric brain tumors provides a challenge. 3,4-dihydroxy-6-[¹⁸F]fluoro-L-phenylalanine (¹⁸F-FDOPA) PET/MRI has not been previously studied as a tool to evaluate early response to antiangiogenic therapy in children. The purpose of this study was to evaluate the safety and feasibility of using ¹⁸F-FDOPA PET/MRI to assess response to bevacizumab in children with relapsed brain tumors.<h4>Materials and methods</h4>Six patients with recurrent gliomas (5 low-grade, 1 high-grade) planned to undergo treatment with bevacizumab were enrolled. ¹⁸F-FDOPA PET/MRI scans were obtained prior to and 4 weeks following the start of treatment, and these were compared with the clinic2018-01-01T00:00:00Z2018 Mar2025-04-04T14:02:21.618Z2019-07-30T07:00:30ZS-EPMC59098072969292210.1093/nop/npx008